Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Liabilities: 2011-2024

Historic Total Liabilities for RedHill Biopharma (RDHL) over the last 13 years, with Dec 2024 value amounting to $22.7 million.

  • RedHill Biopharma's Total Liabilities rose 3.75% to $22.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $133.1 million, marking a year-over-year decrease of 57.54%. This contributed to the annual value of $22.7 million for FY2024, which is 8.33% up from last year.
  • Per RedHill Biopharma's latest filing, its Total Liabilities stood at $22.7 million for FY2024, which was up 8.33% from $21.0 million recorded in FY2023.
  • RedHill Biopharma's 5-year Total Liabilities high stood at $172.3 million for FY2021, and its period low was $2.6 million during FY2022.
  • Moreover, its 3-year median value for Total Liabilities was $21.0 million (2023), whereas its average is $15.4 million.
  • As far as peak fluctuations go, RedHill Biopharma's Total Liabilities surged by 1,080.23% in 2020, and later crashed by 98.48% in 2022.
  • RedHill Biopharma's Total Liabilities (Yearly) stood at $166.4 million in 2020, then climbed by 3.57% to $172.3 million in 2021, then tumbled by 98.48% to $2.6 million in 2022, then surged by 699.77% to $21.0 million in 2023, then increased by 8.33% to $22.7 million in 2024.